OBJECTIVES

Due to lack of reliable and generalizable datasets, knowledge about the real-world treatment of advanced non-small-cell lung cancer (aNSCLC) patients is still limited. The objective of this study was to assess progression-free survival (PFS) and overall survival (OS) of aNSCLC patients since start of a first-line (1L) systemic treatment in German clinical practice.

METHODS

We analyzed patients included in a new electronic medical record databank targeting German oncology patients (INGRESS-Indivumed Liquid Biopsy RWE oncology database). All aNSCLC patients who received a 1L treatment were included. PFS and OS were assessed by Kaplan-Meier survivor function. PFS was defined as time between start of 1L treatment until death or switch to another systemic therapy.

RESULTS

We observed 485 1L-aNSCLC patients (mean age 68.8 years, 42.0% female, 64.3% IIIb, 35.7% IV). In 76.3% of patients, a mutation/immunochemistry test was done (7.4% EGFR+, 29.9% PDL-1, 1.8% ALK+). 64.7% of patients received a 2L treatment, 30.9% a 3L treatment. Most often observed 1L treatment was carboplatin in wild-type, EGFR+ and ALK+ patients, pembrolizumab in PDL-1.

Mean PFS since start of 1L treatment was 456 days (95%-CI:408-504; median: 242). Mean OS since start of 1L treatment was 661 days (95%-CI:611-711; median: not reached).

In analysed subgroups mean PFS/OS was: 476/673 days for stage IIIb, 412/625 days for stage IV, 474/663 days for wild-type, 472/640 days for EGFR+, 325/576 days for PDL-1, and 284/465 days for ALK+.

CONCLUSIONS

The Indivumed Liquid Biopsy RWE oncology database provides valuable data on mutation test results and PFS/OS in German clinical practice. Still, not all patients receive a mutation testing. Moreover, a substantial percentage of EGFR+/ALK+ does not seem to receive targeted therapies.